Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Cara licenses Enteris' Peptelligence to develop oral formulation of Korsuva

Executive Summary

Enteris BioPharma Inc. granted Cara Therapeutics Inc. a non-exclusive worldwide license (excluding Japan and South Korea) to its Peptelligence drug delivery technology to use in the development, manufacture, and commercialization of Cara's oral Korsuva (difelikefalin; CR845), a long-acting synthetic peptide peripheral kappa opioid receptor (KOR) agonist.

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies